Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating condition of the central nervous system that presents unique diagnostic and prognostic challenges. While clinicians readily utilize fluid markers in multiple sclerosis and neuromyelitis optica spectrum disorder, the precise utility of blood-based tools in MOGAD has remained less clear. Evaluating neuronal and astrocytic injury through blood tests offers a non-invasive window into disease activity. Emerging evidence demonstrates that measuring serum biomarkers in MOGAD can substantially refine our understanding of disease severity, acute tissue destruction, and longitudinal patient trajectory.

Understanding Serum Biomarkers in MOGAD Pathophysiology

Neuroinflammatory cascades in MOGAD trigger distinct cellular injuries within the central nervous system. Serum neurofilament light chain (sNfL) serves as an established surrogate for acute neuro-axonal destruction. When axons suffer inflammatory insult, structural neurofilaments release into the interstitial space and diffuse into peripheral circulation. Consequently, elevated sNfL levels signify ongoing neuronal injury during inflammatory bouts.

Conversely, serum glial fibrillary acidic protein (sGFAP) reflects astrocytic activation and injury. Astrocytes play an indispensable role in maintaining the blood-brain barrier and regulating neurovascular integrity. Although MOGAD primarily targets oligodendrocytes and myelin sheaths, reactive astrogliosis and secondary astrocytic distress frequently accompany severe inflammatory episodes. Therefore, quantifying both sNfL and sGFAP provides complementary biological information regarding axonal degradation and glial involvement.

Historically, lumbar punctures provided the only reliable access to these central nervous system proteins. However, ultra-sensitive single-molecule array (Simoa) technology now allows clinicians to measure minute picogram concentrations directly from routine peripheral blood draws. This technological leap enables frequent, longitudinal monitoring without subjecting patients to repeated invasive spinal taps.

Key Findings from the MULTIMOGAD Study

The landmark MULTIMOGAD study evaluated 89 adult patients with confirmed MOGAD across multiple European referral centers. Investigators collected serum samples at baseline within three months of disease onset and at a structured follow-up interval beyond six months. They measured both sNfL and sGFAP concentrations to determine their dynamic trajectories and correlation with clinical parameters.

The study demonstrated that baseline concentrations of both sNfL and sGFAP were substantially elevated during acute disease onset. Over time, these elevated concentrations exhibited significant reductions toward baseline physiological levels at follow-up (p < 0.001 for sNfL and p = 0.027 for sGFAP). This marked clearance demonstrates that acute MOGAD attacks provoke an immediate surge of structural protein shedding that subsides as inflammation resolves.

Additionally, multivariable models revealed that higher baseline biomarker concentrations correlated directly with the severity of acute attacks. These objective biochemical measurements closely mirrored clinician-scored neurological impairment. Consequently, the findings confirm that peripheral biomarker surges reliably reflect the magnitude of acute central nervous system parenchymal damage during clinical relapses.

Correlation with Attack Severity and Clinical Phenotype

The MULTIMOGAD investigators identified significant associations between biomarker concentrations and neurological disability, quantified by the Expanded Disability Status Scale (EDSS). Specifically, both sNfL (β = 0.15, p = 0.002) and sGFAP (β = 0.14, p < 0.001) correlated positively with peak EDSS scores recorded during acute attacks. Thus, patients experiencing more disabling motor, sensory, or cerebellar deficits exhibited proportionally higher biomarker concentrations.

Interestingly, biomarker levels varied markedly according to clinical presentation. Patients presenting exclusively with isolated optic neuritis demonstrated significantly lower sNfL (β = -0.69, p = 0.007) and sGFAP (β = -0.42, p = 0.016) levels compared to those with transverse myelitis or acute disseminated encephalomyelitis. This distinction likely reflects the smaller anatomical volume of tissue involved in isolated optic nerve inflammation relative to extensive spinal cord or brain lesions.

Furthermore, the reduction in biomarker levels between baseline and follow-up (the biomarker delta) correlated strongly with clinical recovery. Patients with greater drops in sNfL and sGFAP demonstrated superior improvements in functional scores. Therefore, resolving biomarker titers closely track structural healing and functional clinical stabilization in convalescent patients.

Prognostic Value of sNfL and sGFAP Dynamics

Beyond capturing cross-sectional disease severity, baseline biomarker levels provide substantial prognostic insight into future disease behavior. A central challenge in managing MOGAD involves distinguishing patients destined for a monophasic course from those at high risk of recurrent relapses. Early risk stratification remains vital for guiding long-term immunosuppressive maintenance therapy.

In the MULTIMOGAD cohort, baseline sNfL emerged as an independent predictor of disease recurrence. Cox proportional hazards analysis revealed that elevated baseline sNfL doubled the risk of future relapses (Hazard Ratio 2.06, 95% Confidence Interval 1.41 to 3.01, p < 0.001). Patients exhibiting substantial neuro-axonal injury at onset were significantly more prone to subsequent neuroinflammatory events.

Meanwhile, sGFAP dynamics provided valuable information regarding the recovery trajectory of glial architecture. Monitoring longitudinal shifts in both biomarkers allows clinicians to identify ongoing, subclinical tissue stress even before overt neurological deficits manifest. Thus, combining these two markers establishes a comprehensive biochemical framework for anticipating attack recurrence and tracking long-term disability progression.

Clinical Implications for Neurological Practice

The integration of serum biomarkers into routine neurological workflows offers practical benefits for managing neuroinflammatory disorders. First, obtaining baseline sNfL and sGFAP levels during an acute attack establishes an objective benchmark of initial tissue damage. This biochemical profile assists clinicians in assessing attack severity beyond subjective physical examinations.

Second, biomarker quantification helps clinicians gauge therapeutic efficacy. A failure of sNfL or sGFAP levels to decline after high-dose corticosteroid therapy or plasma exchange may indicate unresolved active inflammation. In such scenarios, clinicians might consider intensifying acute rescue treatments or expediting the initiation of maintenance immunotherapy.

Third, risk stratification informed by sNfL levels aids shared decision-making regarding long-term maintenance therapy. Patients with highly elevated baseline sNfL may benefit from early maintenance immunosuppression, such as azathioprine, mycophenolate mofetil, or targeted monoclonal antibodies. Conversely, patients with modest biomarker elevations and complete clinical recovery might safely undergo structured observation, sparing them unnecessary immunosuppressive exposure.

Future Directions in MOGAD Monitoring

While the findings from the MULTIMOGAD study represent significant progress, several operational hurdles warrant consideration before widespread clinical adoption. Standardized reference intervals stratified by age and renal function remain necessary, as peripheral clearance mechanisms influence circulating biomarker concentrations. Additionally, access to ultra-sensitive assay platforms must expand across global diagnostic laboratories.

Future prospective studies should investigate whether serial biomarker measurements can detect impending relapses during remission phases. Tracking subclinical biomarker elevations could enable pre-emptive therapeutic adjustments before permanent structural damage occurs. Furthermore, comparing biomarker profiles across MOGAD, multiple sclerosis, and aquaporin-4-positive neuromyelitis optica spectrum disorder will help refine differential diagnostic algorithms.

Ultimately, incorporating circulating biomarkers alongside clinical evaluation and magnetic resonance imaging will drive personalized management strategies in MOGAD. Combining fluid biomarkers with neuroimaging will empower clinicians to deliver timely, precision-guided neuroprotective interventions.

What are the primary serum biomarkers evaluated in MOGAD?

The two primary serum biomarkers are neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP). sNfL reflects acute neuro-axonal destruction, whereas sGFAP serves as a sensitive indicator of astrocytic activation and injury during central nervous system inflammation.

How do sNfL levels correlate with clinical relapses in MOGAD?

Baseline sNfL concentrations independently predict future relapse risk in MOGAD. According to the MULTIMOGAD study, elevated baseline sNfL levels were associated with a more than two-fold increase in the risk of experiencing subsequent clinical attacks over time.

Why are biomarker levels lower in isolated optic neuritis?

Isolated optic neuritis typically involves a smaller volumetric area of central nervous system tissue compared to multifocal encephalomyelitis or extensive transverse myelitis. Consequently, the total quantity of structural proteins released into the bloodstream remains lower despite significant focal visual symptoms.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician or other qualified health provider with any questions they may have regarding a medical condition. Clinicians should use their own clinical judgment and not rely solely on any information provided by this resource. Refer to the latest local and national guidelines for clinical practice.

References

1. Marignier R et al. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study. J Neurol Neurosurg Psychiatry. 2025 Aug 14. doi: 10.1136/jnnp-2024-335137. PMID: 39939136.


2. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Consortium proposed criteria. Lancet Neurol. 2023;22(3):268-282.


3. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018;90(21):e1858-e1869.


4. Mariotto S, Farinazzo A, Monaco S, et al. Serum neurofilament light chain in NMOSD and MOGAD: Clinical and diagnostic utility. Mult Scler. 2021;27(12):1858-1867.